GlassScriptPhysician profile
Geoffrey Alilonu
NPI 1144295221
$8,236.07
in general payments reported to CMS, 2019-2025
30 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $773 · 2021: $912 · 2022: $1,431 · 2023: $1,191 · 2024: $1,358 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,948 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.18 |
| Education | $185.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,514.61 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $1,098.69 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $1,082.50 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $813.89 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Akebia Therapeutics INC | $750.92 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $519.46 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $435.81 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $265.13 | 2023-2024 | |
| Glaxosmithkline, LLC. | $196.07 | 2021-2025 | Benlysta, Jesduvroq, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $172.42 | 2021-2025 | |
| Horizon Therapeutics Plc | $159.33 | 2023 | Krystexxa |
| Novo Nordisk INC | $157.86 | 2025 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $151.18 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $138.41 | 2024-2025 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $120.12 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.21 | 2023-2025 | |
| Renalytix Ai, INC. | $91.50 | 2022 | |
| Mallinckrodt Enterprises LLC | $77.29 | 2019 | |
| Ardelyx, INC. | $69.90 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $65.39 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $60.84 | 2022-2023 | Lupkynis |
| Shire North American Group INC | $35.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $25.15 | 2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $24.31 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.32 | 2025 | |
| Baxter Healthcare | $18.98 | 2019 | |
| Nxstage Medical, INC. | $18.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.58 | 2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $17.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Alilonu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.